TABLE 5

Bile acid concentrations in bile, plasma, and liver (data of Fig. 2A) of FRGN, mFRGN, and hFRGN livers (n = 4–8, mean ± S.E.M.)

Bile (μM)Plasma (μM)Liver (nmol/g)
FRGNmFRGNhFRGNhFRGN to FRGN RatioFRGNmFRGNhFRGNhFRGN to FRGN RatioFRGNmFRGNhFRGNhFRGN to FRGN Ratio
Total BA23,137 ± 429077,369 ± 31,272241,840 ± 47,453*10.56.6 ± 3.113.3 ± 4.7321 ± 40.1*4976.4 ± 24.2121 ± 38.0429 ± 42.2*5.6
Primary + secondary BA252 ± 98288 ± 882752 ± 698*10.92.4 ± 1.54.4 ± 2.539.4 ± 14.8*1744.8 ± 15.275.9 ± 25.68.1 ± 4.0*0.2
Tauro-conjugated BA22,857 ± 426277,027 ± 31,201183,520 ± 32,047*84.2 ± 1.68.9 ± 3.1153 ± 29.1*3731.3 ± 10.245.5 ± 12.6382 ± 39.8*12
Glyco-conjugated BA28 ± 1052 ± 3355,567 ± 17,757*2,003<0.01<0.01129 ± 36.6*a0.16 ± 0.09<0.0139.3 ± 9.7*240
α-MCA9.3 ± 4.824.9 ± 11.388.0 ± 17.3*9.50.09 ± 0.050.56 ± 0.341.81 ± 0.9720.11.08 ± 0.324.61 ± 0.970.35 ± 0.12*0.32
tα-MCA522 ± 1505580 ± 1,9049536 ± 3,077*18.30.13 ± 0.040.55 ± 0.217.13 ± 2.93*550.32 ± 0.180.91 ± 0.309.17 ± 2.12*29
β-MCA63.3 ± 22.9143 ± 41.895.6 ± 19.21.51.22 ± 0.911.83 ± 1.213.11 ± 0.602.531.7 ± 11.854.6 ± 21.91.23 ± 0.24*0.04
tβ-MCA9507 ± 272035,606 ± 11,72116,354 ± 3,5301.71.93 ± 0.895.26 ± 1.9811.8 ± 2.67*6.10.75 ± 0.388.14 ± 4.5431.2 ± 3.52*42
ω-MCA61.6 ± 27.668.7 ± 21.924.5 ± 5.30.40.64 ± 0.390.98 ± 0.752.43 ± 0.653.85.84 ± 2.37.51 ± 2.880.35 ± 0.08*0.06
tω-MCA4863 ± 1,26511,766 ± 5,8491021 ± 308*0.210.58 ± 0.221.31 ± 0.472.61 ± 0.48*4.51.71 ± 0.994.03 ± 1.673.23 ± 0.921.9
MCA0.1 ± 0.15<0.011.4 ± 0.68140.01 ± 00.01 ± 0.010.10 ± 0.02*100.49 ± 0.170.63 ± 0.130.03 ± 0.01*0.06
CA117 ± 4751 ± 162502 ± 680*21.30.2 ± 0.10.7 ± 0.616.2 ± 12.3*762.89 ± 1.053.22 ± 0.684.58 ± 3.361.6
tCA7318 ± 148422,085 ± 11,681109,010 ± 24,806*14.91.33 ± 0.491.47 ± 0.5061.4 ± 16.9*4625.1 ± 8.428.1 ± 7.5165 ± 36.4*6.6
gCA28 ± 1052 ± 3250,400 ± 15,742*1,816<0.01<0.0124.4 ± 10.9*0.08 ± 0.05<0.0117.1 ± 7.0*207
CDCA<0.01<0.011.96 ± 0.27*0.04 ± 0.020.09 ± 0.060.37 ± 0.04*9.21.35 ± 0.363.06 ± 0.46<0.01*<0.01
tCDCA160 ± 33763 ± 1238,503 ± 3,440*530.07 ± 0.030.20 ± 0.072.61 ± 0.98*380.80 ± 0.231.77 ± 0.418.47 ± 1.84*10
gCDCA<0.01<0.01671 ± 287*<0.01<0.010.43 ± 0.15*<0.01<0.010.87 ± 0.27*
DCA<0.01<0.0138.5 ± 12.2*0.07 ± 0.010.12 ± 0.0314.8 ± 2.41*2210.16 ± 0.070.14 ± 0.021.54 ± 0.67*9.8
tDCA367 ± 262581 ± 15136,171 ± 12,732*990.09 ± 0.030.06 ± 0.0266.8 ± 14.7*7252.23 ± 1.161.46 ± 0.21161 ± 18.8*72
gDCA<0.01<0.014200 ± 1925*<0.01<0.01103 ± 29.6*0.06 ± 0.03<0.0121.2 ± 4.9*348
UDCA0.8 ± 0.21.1 ± 0.30.5 ± 0.30.630.06 ± 0.040.09 ± 0.030.13 ± 0.022.21.33 ± 0.282.12 ± 0.58<0.01*<0.01
tUDCA116 ± 28630 ± 2372654 ± 1396*22.90.03 ± 0.010.07 ± 0.020.38 ± 0.11*12.70.38 ± 0.180.88 ± 0.201.74 ± 0.25*4.6
gUDCA<0.01<0.01277 ± 157*<0.01<0.01<0.01NA<0.01<0.010.08 ± 0.08NA
LCA<0.01<0.01<0.01NA0.05 ± 0.03<0.010.02 ± 0.010.4<0.01<0.01<0.01NA
tLCA2.7 ± 1.214.4 ± 3.7269 ± 131*100<0.01<0.010.14 ± 0.070.08 ± 0.010.18 ± 0.061.74 ± 0.43*22
gLCA<0.01<0.0117.9 ± 8.1*<0.01<0.010.31 ± 0.11*0.02 ± 0.02<0.010.07 ± 0.023.5
  • and * denote P < 0.05 compared between mFRGN and FRGN mice and hFRGN and FRGN mice, respectively, using two-tailed Student’s t test or Mann-Whitney test; NA, not applicable.

  • a